Plexus (PLXS) Q3 2025 earnings review
Strong Execution Drives Beat and Raise; Margin Rebounds to 6% Target
Plexus delivered a strong Q3, beating guidance on both revenue and EPS. Revenue grew 6.0% YoY to $1.018 billion, marking an acceleration from the prior quarter. Critically, Non-GAAP Operating Margin rebounded to the company's 6.0% target after a dip in Q2, demonstrating solid operational execution. The company issued Q4 guidance that implies continued sequential growth and raised its full-year free cash flow forecast to approximately $100 million. This performance is underpinned by strong new program wins ($250M annualized) and an expanding opportunity funnel, suggesting share gains are offsetting a mixed demand environment.
🐂 Bull Case
Non-GAAP operating margin returned to the company's 6.0% goal. Management has now achieved this target in three of the last four quarters, proving its ability to drive operational efficiencies and manage costs effectively.
The company secured $250 million in annualized revenue from new wins, a rebound from the prior two quarters. The funnel of qualified opportunities also expanded to a robust $3.6 billion, providing good visibility for future growth.
Management increased its full-year FY25 free cash flow forecast to approximately $100 million. This strong cash generation supports debt reduction and an active $100 million share repurchase program, creating direct shareholder value.
🐻 Bear Case
Q4 guidance implies a reversal in YoY revenue growth to -0.5% at the midpoint, a sharp deceleration from Q3's +6.0% growth. YoY Non-GAAP EPS growth is also guided to slow dramatically to just +2.4%.
Growth is heavily reliant on the Healthcare/Life Sciences segment (+10.5% YoY). The Industrial (+3.0%) and Aerospace/Defense (+2.8%) segments are lagging significantly, indicating potential weakness in those end markets.
⚖️ Verdict: 🟢
Bullish. The company is demonstrating excellent execution. The rebound in operating margin to the 6.0% target is a significant achievement and signals strong cost control. While the Q4 guidance implies a growth slowdown from a tough comparison, the momentum in new program wins and the expanding sales funnel provide confidence in the company's preliminary healthy outlook for FY26. The ability to gain share in a mixed environment is the more compelling narrative.
Key Themes
Healthcare/Life Sciences Segment Powers Growth
The Healthcare/Life Sciences segment was the standout performer, growing 10.5% YoY to $420 million. This growth is being driven by multiple ongoing program ramps and strong new wins, including a substantial follow-on award for a device that treats atrial fibrillation. The segment's strength is currently masking more modest performance elsewhere in the business.
New Business Wins Rebound
After two quarters of around $210M, new program wins jumped to $250M in annualized revenue in Q3. The funnel of qualified manufacturing opportunities also expanded to $3.6 billion. Management credits their focus on 'zero defects and perfect delivery' for share gains and winning new customers with products in high-growth technology areas.
Lagging Growth in Industrial and A&D Segments
While the overall results were strong, the underlying performance is unbalanced. The Industrial segment grew just 3.0% YoY, impacted by some program pushouts in the semi-cap subsector. Similarly, Aerospace/Defense grew only 2.8% YoY, with Q4 guidance for the segment to be flat sequentially. These two segments represent over 58% of total revenue and their sluggishness presents a risk to the overall growth profile.
Navigating Macro Headwinds
Management noted they are delivering growth despite 'muted end market demand' and 'uncertainties created by tariffs.' While the company passes tariff costs on to customers and has not seen a direct impact on demand, the challenging macro environment remains a key external risk factor that could affect customer forecasts and program ramp timelines.
Engineering Solutions as a Leading Indicator
Management highlighted that the revenue contribution and performance of its higher-margin Engineering Solutions was strong, and the overall wins performance included the 'best in more than 2 years' for the Aerospace & Defense sector. Historically, a strong engineering pipeline acts as a leading indicator for future complex manufacturing revenue, supporting a positive outlook for FY26 and beyond.
Other KPIs
ROIC improved to 14.1%, the highest level in nearly four years and 520 basis points above the company's weighted average cost of capital. This accelerating trend reflects improved profitability and sustained discipline in working capital management, particularly inventory reduction, demonstrating high-quality returns on capital.
The company generated positive free cash flow of $13.2 million, bringing the year-to-date total to $56.8 million. Based on this strong performance, management raised its full-year FY25 FCF projection to approximately $100 million, providing ample capacity for the new $100 million share repurchase program and further debt reduction.
Management successfully drove a sixth consecutive quarterly reduction in the gross inventory balance. Inventory days improved by 4 days sequentially to 128. This continued progress on working capital initiatives is a key driver behind the strong FCF generation and improving ROIC.
Guidance
Reversing. The guidance midpoint of $1.045 billion implies a sequential increase of 2.6%. However, it represents a YoY decline of -0.5% from a strong Q4 last year. This marks a sharp deceleration from the +6.0% YoY growth achieved in Q3.
Decelerating. The midpoint of $1.895 is roughly flat sequentially but implies just 2.4% YoY growth. This is a significant slowdown compared to the 30-40% YoY growth seen in the first three quarters of FY25, reflecting the tougher revenue comparison and slight margin pressure.
Stable. The midpoint of 5.9% is a slight dip from 6.0% in Q3. Management attributes this to higher incentive compensation expenses and initial startup costs for the new manufacturing facility in Penang, Malaysia. The range remains consistent with the company's long-term target.